Brain Tumor Treatments: Less-Toxic
Sponsored By
Brain tumor book
Please Click On The Above Banner For More Details
Braintumor Website

Search Term: Less-Toxic
Please scroll down past the trials to see pages on this site about this topic!

The term Less Toxic includes targeted treatments. While they may be less toxic than the older chemotherapies, they may still have significant toxicities and side effects.

  Showing Treatment 1 to 25 of 240 Next 25 Location Last Updated
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Gießen, Germany 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Montreal, Canada 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Hamburg, Germany 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Graz, Austria 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Innsbruck, Austria 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Wien, Austria 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Marseille, France 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Nancy, France 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Rouen, France 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Bonn, Germany 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Freiburg, Germany 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Günzburg, Germany 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Hannover, Germany 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Heidelberg, Germany 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Leipzig, Germany 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Magdeburg, Germany 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Münster, Germany 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Regensburg, Germany 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Bangalore, India 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Bangalore, India 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Bangalore, India 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Chennai, India 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Cochin, India 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Hyderabaad, India 08/31/2010
Details Efficacy and Safety of AP 12009 (trabedersen) in Patients With Recurrent or Refractory Anaplastic Astrocytoma (SAPPHIRE) Kolkata, India 08/31/2010

(Relevance) Page Title - click title to go to the page!

  (0.8510)   Brain Tumor Treatments: Less-Toxic
  (0.7967)   Search for a Specific Trial or Treatment
  (0.7967)   Emerging Med Trials Matcher
  (0.7967)   Brain Tumor Treatments: Israel
  (0.7742)   Brain Tumor Guide
  (0.7742)   Brain Tumor Treatments: China PR
  (0.7742)   Brain Tumor Treatments: Chemotherapy
  (0.7742)   Brain Tumor Chat Room
  (0.7742)   Brain tumor Chat room registration
  (0.7742)   Problem Report Received
  (0.7742)   Brain Tumor Chat Room Problem
  (0.7742)   Brain Tumor Treatments: Netherlands
  (0.7742)   Brain Tumor Treatments: Nebraska
  (0.7742)   Brain Tumor Treatments: North Dakota
  (0.7742)   Trials without an NCT number
  (0.7742)   Trials by NCT number
  (0.7742)   Brain Tumor Treatments: North Carolina
  (0.7742)   Musella Foundation
  (0.7742)   Brain Tumor Treatments: Montana
  (0.7742)   Brain Tumor Treatments: Mississippi
  (0.7742)   Mohammad Abdollahian
  (0.7742)   Brain Tumor Treatments: Missouri
  (0.7742)   Brain Tumor Treatments: Minnesota
  (0.7742)   Brain Tumor Treatments: Michigan
  (0.7742)   TEST
  (0.7742)   virtualtrials.com/menu2006b.cfm
  (0.7742)   virtualtrials.com/menu2006.cfm
  (0.7742)   Meningioma List
  (0.7742)   Meningioma List
  (0.7742)   Memorials
  (0.7742)   Memorials
  (0.7742)   Memorial
  (0.7742)   Medulloblastoma
  (0.7742)   Brain Tumor Treatments: Maine
  (0.7742)   Brain Tumor Treatments: Maryland
  (0.7742)   Map
  (0.7742)   Map
  (0.7742)   Map
  (0.7742)   Map
  (0.7742)   Brain Tumor Treatments: Malaysia
  (0.7742)   Newsletter And Daily News Update!
  (0.7742)   Mailbox
  (0.7742)   Brain Tumor Treatments: Massachusetts
  (0.7742)   Brain Tumor Treatments: Less Toxics
  (0.7742)   Online Support Groups
  (0.7742)   Links (webTV version)
  (0.7742)   Links to More Brain Tumor Information
  (0.7742)   Links to More Brain Tumor Information
  (0.7742)   Links to More Brain Tumor Information
  (0.7742)   Add a Links to Brain Tumor Information
  (0.7742)   Add a Links to Brain Tumor Information
  (0.7742)   Links to More Brain Tumor Information
  (0.7742)   Chemotherapy For Brain Tumors
  (0.7742)   Letter Writing Campaign
  (0.7742)   Brain Tumor Treatments: Less Toxics
  (0.7742)   Brain Tumor Treatments: Louisiana
  (0.7742)   Brain Tumor Treatments: Kentucky
  (0.7742)   Brain Tumor Treatments: Kansas
  (0.7742)   Karnofsky Score
  (0.7742)   Jim Racich Memorial
  (0.7742)   Stereotactic Radiosurgery
  (0.7742)   Mailing Lists
  (0.7742)   Mailing Lists
  (0.7742)   Brain Tumor Treatments: Japan
  (0.7742)   Brain Tumor Treatments: Italy
  (0.7742)   Brain Tumor Chat Room Question
  (0.7742)   Brain Tumor Chat room
  (0.7742)   Brain Tumor Trials And Treatments
  (0.7742)   Brain Tumor Trials And Treatments
  (0.7742)   Brain Tumor Trials And Treatments
  (0.7742)   Brain Tumor Trials And Treatments
  (0.7742)   Brain Tumor Trials And Treatments
  (0.7742)   Brain Tumor Trials And Treatments
  (0.7742)   Brain Tumor Trials And Treatments
  (0.7742)   Brain Tumor Treatments: Indiana
  (0.7742)   Immunotherapies, biological and targeted therapies
  (0.7742)   Immunotherapies, biological and targeted therapies
  (0.7742)   Image Guided Surgery
  (0.7742)   Brain Tumor Treatments: Illinois
  (0.7742)   IFN-Beta Gene Transfer
  (0.7742)   Brain Tumor Treatments: Idaho
  (0.7742)   Brain Tumor Treatments: Iowa
  (0.7742)   2003 Pediatric Brain Tumor Confernce
  (0.7742)   Video Library: Brainstorming Long Island 2004
  (0.7742)   Hockey fundraiser
  (0.7742)   Hockey fundraiser
  (0.7742)   Brain Tumor Treatments: Hawaii
  (0.7742)   Human Corticotropin-Releasing Factor (hCRF)
  (0.7742)   Brain Tumor Chat Room
  (0.7742)   Brain Tumor Chat room




Home | Brain Tumor Guide | Search | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Chat | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us | Doctors Address Book



Copyright (c) 1993 - 2010 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By
World Wide Websites